candidate ZPL389 and the strategies for the control of impurities are outlined in detail. Selective salt formation at several stages was pivotal to controlling the process impurities. The extensive optimization of the N-methylation of a Boc-protected amine with dimethyl sulfate and of a nucleophilic aromatic substitution without the use of metal catalysts led to a robust, scalable process. The process was
详细概述了候选药物ZPL389的后期制造工艺的发展和杂质控制策略。在几个阶段形成选择性盐对控制工艺杂质至关重要。Boc保护的胺与
硫酸二甲酯的N-甲基化以及亲核芳香族取代的广泛优化,而无需使用
金属催化剂,这导致了稳健的,可扩展的过程。该过程以> 100公斤的规模进行了演示。总体而言,实现了
原料药质量的提高,产量的提高以及过程质量强度的降低。